antirheumatic


Also found in: Medical.

antirheumatic

(ˌæntɪruːˈmætɪk)
adj
acting against rheumatism
n
a drug or treatment that acts against rheumatism
Translations
References in periodicals archive ?
Scientists analysed the records of patients taking disease-modifying antirheumatic drugs (DMARDs) and those who were not.
Patients taking disease-modifying antirheumatic medications for systemic sclerosis appear to have a decreased response to pneumococcal vaccines, a Swedish study has determined.
Methotrexate is the first-line disease-modifying antirheumatic drug used in patients with RA (Annals of the Rheumatic Diseases, September 2017).
The US Food and Drug Administration (FDA) has granted approval to Pfizer for its Xeljanz 5 mg twice daily (BID) and Xeljanz XR (tofacitinib) extended release 11 mg once daily (QD) to treat adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
According to the company, the SPIRIT-P1 study evaluated the safety and efficacy of Taltz compared to placebo in patients with active PsA who had never been treated with a biologic disease-modifying antirheumatic drug.
The findings are encouraging because patients with rheumatoid arthritis have a higher risk of developing shingles than other adults, and tofacitinib and certain other disease-modifying antirheumatic drugs are thought to further increase this risk.
Most participants in the study had longstanding RA and were taking disease-modifying antirheumatic drugs.
A human monoclonal antibody, Kevzara is indicated for use in patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
The average duration of RA among all participants was 17 years, and 58 percent of the participants were taking a disease-modifying antirheumatic drug, such as methotrexate, sulfasalazine (Azulfidine), and hydroxychloroquine (Plaquenil).
Researchers compared the health records of more than 11,000 RA patients taking TNFis with the records of about 3,000 RA patients taking synthetic disease-modifying antirheumatic drugs (sDMARDs), another common RA treatment.
In this comprehensive review of 3,742 relevant publications, there was general agreement that initial treatment should center on disease-modifying antirheumatic drugs (DMARDs) plus systemic glucocorticoids.
Editor's Note: The authors remark that MK-7 is significantly less toxic than antirheumatic drugs and it has the additional benefit of protecting against osteoporosis.